The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citationTreatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citationHadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citationPETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citationPulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180
Research works printed but not linked: 3
- Gurtner HP, 1985, Cor Vasa, 27, 160
- Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
- Russel LA, 1992, Am Rev Respir Dis, 145, A717
Cited by
Sorted by citations
Items 101–200 of 999
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects
Gomez‐Arroyo, J. G., Saleem, S. J., Mizuno, S., Syed, A. A., Bogaard, H. J., Abbate, A., Taraseviciene‐Stewart, L., Sung, Y. K., Kraskauskas, D., Farkas, D., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00362.2011 · Cited by 202
Higenbottam, T., Butt, A. Y., McMahon, A., Westerbeck, R. N., & Sharples, L. D. (1998) · Heart · doi:10.1136/hrt.80.2.151 · Cited by 208
Self-citationManagement strategies for patients with pulmonary hypertension in the intensive care unit*
Zamanian, R. T., Haddad, F., Doyle, R. L., & Weinacker, A. B. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000280433.74246.9e · Cited by 205
Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension
Marcos, É., Adnot, S., Pham, M. H., Nosjean, A., Raffestin, B., Hamon, M., & Eddahibi, S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1212oc · Cited by 203
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
Dietrich, M. O., & Horváth, T. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3739 · Cited by 205
Blackburn, G. L., Kanders, B. S., Lavin, P. T., Keller, S. M., & Whatley, J. (1997) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.2.409 · Cited by 202
PATHOBIOLOGY OF PULMONARY HYPERTENSION
Hervé, P., Humbert, M. J. C., Sitbon, O., Parent, F., Nunès, H., Legal, C., Garcia, G., & Simonneau, G. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70283-5 · Cited by 199
Self-citationThe Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure
Boucherat, O., Agrawal, V., Lawrie, A., & Bonnet, S. (2022) · Circulation Research · doi:10.1161/circresaha.121.319971 · Cited by 210
Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?
Chin, K. M., Channick, R. N., & Rubin, L. J. (2006) · Chest · doi:10.1378/chest.130.6.1657 · Cited by 193
Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension
Marcos, É., Fadel, É., Sanchez, O., Humbert, M. J. C., Dartevelle, P., Simonneau, G., Hamon, M., Adnot, S., & Eddahibi, S. (2004) · Circulation Research · doi:10.1161/01.res.0000126847.27660.69 · Cited by 192
Self-citationThe Genetics of Pulmonary Arterial Hypertension
Austin, E. D., & Loyd, J. E. (2014) · Circulation Research · doi:10.1161/circresaha.115.303404 · Cited by 193
Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling?
Morrell, N. W. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200605-118sf · Cited by 190
Anorexigens and Pulmonary Hypertension in the United States
Rich, S., Rubin, L. J., Walker, A. M., Schneeweiß, S., & Abenhaim, L. (2000) · CHEST Journal · doi:10.1378/chest.117.3.870 · Cited by 190
Self-citation5‐HYDROXYTRYPTAMINE IN THE CARDIOVASCULAR SYSTEM: FOCUS ON THE SEROTONIN TRANSPORTER (SERT)
Ni, W., & Watts, S. W. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04410.x · Cited by 189
Yu, Y., Keller, S. H., Remillard, C. V., Safrina, O., Nicholson, A., Zhang, S. L., Jiang, W., Vangala, N., Landsberg, J. W., Wang, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.782458 · Cited by 189
Weiss, B. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1701 · Cited by 186
How to write a patient case report
Cohen, H. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060182 · Cited by 184
Heal, D. J., Smith, S. L., Fisas, A., Codony, X., & Buschmann, H. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.006 · Cited by 191
Therapeutic and adverse actions of serotonin transporter substrates
Rothman, R. B., & Baumann, M. H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00234-6 · Cited by 181
Fatal Pulmonary Hypertension Associated with Short-Term Use of Fenfluramine and Phentermine
Mark, E. J., Patalas, E. D., Chang, H. T., Evans, R. J., & Kessler, S. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370904 · Cited by 180
Pulmonary hypertension surveillance--United States, 1980-2002.
Hyduk, A., Croft, J. B., Ayala, C., Zheng, K. H., Zheng, Z., & Mensah, G. A. (2005) · PubMed · Cited by 179
High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension
Chu, J. W., Kao, P. N., Faul, J. L., & Doyle, R. L. (2002) · CHEST Journal · doi:10.1378/chest.122.5.1668 · Cited by 178
Pulmonary Hypertension after Splenectomy?
Hoeper, M. M., Niedermeyer, J., Hoffmeyer, F., Flemming, P., & Fabel, H. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00014 · Cited by 177
Serotonin Inhibits Voltage-Gated K + Currents in Pulmonary Artery Smooth Muscle Cells
Cogolludo, A. L., Moreno, L., Lodi, F., Frazziano, G., Cobeño, L., Tamargo, J. L., & Pérez‐Vizcaíno, F. (2006) · Circulation Research · doi:10.1161/01.res.0000216858.04599.e1 · Cited by 175
Long-term Pharmacotherapy of Obesity 2000
Glazer, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.15.1814 · Cited by 167
Pharmacological targeting of the serotonergic system for the treatment of obesity
Garfield, A. S., & Heisler, L. K. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164152 · Cited by 170
Current and future treatments of pulmonary arterial hypertension
Sommer, N., Ghofrani, H. A., Pak, O., Bonnet, S., Provencher, S., Sitbon, O., Rosenkranz, S., Hoeper, M. M., & Kiely, D. G. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15016 · Cited by 165
Remillard, C. V., Tigno, D. D., Platoshyn, O., Burg, E. D., Brevnova, E. E., Conger, D., Nicholson, A., Rana, B. K., Channick, R. N., Rubin, L. J., et al. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00405.2006 · Cited by 163
Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure
Hester, J., Ventetuolo, C. E., & Lahm, T. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190011 · Cited by 183
Douketis, J. D., Feightner, J., Attia, J., & Feldman, W. F. (1999) · Europe PMC (PubMed Central) · Cited by 159
Lawrie, A., Spiekerkoetter, E. F., Martinez, E. C., Ambartsumian, N. S., Sheward, W. J., MacLean, M. R., Harmar, A. J., Schmidt, A.-M., Lukanidin, E. M., & Rabinovitch, M. (2005) · Circulation Research · doi:10.1161/01.res.0000176025.57706.1e · Cited by 156
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
Ioannides‐Demos, L. L., Proietto, J., Tonkin, A. M., & McNeil, J. J. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00001 · Cited by 152
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 153
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Rubin, L. J., & Badesch, D. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00009 · Cited by 149
Pharmacological Therapy of Obesity: Past, Present, and Future
Weigle, D. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030151 · Cited by 148
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Souza, R., Humbert, M. J. C., Sztrymf, B., Jaïs, X., Yaici, A., Pavec, J. L., Parent, F., Hervé, P., Soubrier, F., Sitbon, O., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00104807 · Cited by 145
Self-citationPharmacological Treatment of Obesity: Therapeutic Strategies
Kordik, C. P., & Reitz, A. B. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980521l · Cited by 145
Pulmonary Hypertension Surveillance
George, M. G., Schieb, L. J., Ayala, C., Talwalkar, A., & Levant, S. (2014) · CHEST Journal · doi:10.1378/chest.14-0527 · Cited by 143
Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes
Lam, D. D., & Heisler, L. K. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000245 · Cited by 142
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142
Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension
Zamanian, R. T., Hedlin, H., Greuenwald, P., Wilson, D. M., Segal, J. I., Jorden, M. A., Kudelko, K. T., Liu, J., Hsi, A., Rupp, A., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201705-0943oc · Cited by 141
The maintenance of treatment effects in the long-term management of obesity.
Perri, M. G. (1998) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.1998.tb00172.x · Cited by 141
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
Weill, A., Païta, M., Tuppin, P., Fagot, J., Neumann, A., Simon, D., Ricordeau, P., Montastruc, J., & Allemand, H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2044 · Cited by 140
Treatment of pulmonary arterial hypertension with targeted therapies
O’Callaghan, D. S., Savale, L., Montani, D., Jaïs, X., Sitbon, O., Simonneau, G., & Humbert, M. J. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.104 · Cited by 138
Self-citationRISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
Humbert, M. J. C., Nunès, H., Sitbon, O., Parent, F., Hervé, P., & Simonneau, G. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70284-7 · Cited by 138
Self-citationThe surgical treatment of morbid obesity
Kellum, J. M., DeMaria, E. J., & Sugerman, H. J. (1998) · Current Problems in Surgery · doi:10.1016/s0011-3840(98)80009-9 · Cited by 136
Rothman, R. B., & Baumann, M. H. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00669-4 · Cited by 133
Murphy, D. L., Andrews, A. M., Wichems, C. H., Li, Q., Tohda, M., & Greenberg, B. D. (1998) · PubMed · Cited by 133
Toxicity of Weight Loss Agents
Yen, M., & Ewald, M. B. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0213-7 · Cited by 132
Leary, P. J., Lindstrom, M., Johnson, C. O., Emmons‐Bell, S., Rich, S., Corris, P. A., DuBrock, H. M., Ventetuolo, C. E., Abate, Y. H., Abdelmasseh, M., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00295-9 · Cited by 130
Self-citationFishman, A. P. (1999) · Circulation · doi:10.1161/01.cir.99.1.156 · Cited by 129
Obesity and Pulmonary Hypertension: A Review of Pathophysiologic Mechanisms
Friedman, S. E., & Andrus, B. W. (2012) · Journal of Obesity · doi:10.1155/2012/505274 · Cited by 130
Diagnosis and treatment of pulmonary hypertension.
Nauser, T. D., & Stites, S. W. (2001) · PubMed · Cited by 128
Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension
Hsue, P. Y., Deeks, S. G., Farah, H. H., Palav, S., Ahmed, S. Y., Schnell, A., Ellman, A., Huang, L., Dollard, S. C., & Martin, J. N. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cd42 · Cited by 127
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
Shah, N. P., Wallis, N., Farber, H. W., Mauro, M. J., Wolf, R. A., Mattei, D. G., Guha, M., Réa, D., & Peacock, A. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24174 · Cited by 126
Mechanisms and treatment of pulmonary arterial hypertension
Ghofrani, H. A., Gomberg‐Maitland, M., Zhao, L., & Grimminger, F. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01064-4 · Cited by 134
Reform of Drug Regulation — Beyond an Independent Drug-Safety Board
Ray, W. A., & Stein, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmsb053432 · Cited by 119
Primary Pulmonary Hypertension
Galiè, N., Manes, A., Uguccioni, L., Serafini, F., Rosa, M. D., Branzi, A., & Magnani, B. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.184s · Cited by 120
Heart Failure Induced by Non-Cardiac Drugs
rdal, L. S., & Spigset, O. (2006) · Drug Safety · doi:10.2165/00002018-200629070-00003 · Cited by 119
Inhaled nitric oxide in primary pulmonary hypertension
Ricciardi, M. J., Knight, B. P., Martínez, F. J., & Rubenfire, M. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00361-1 · Cited by 118
A noninvasive algorithm to exclude pre-capillary pulmonary hypertension
Bonderman, D., Wexberg, P., Martischnig, A. M., Heinzl, H., Lang, M., Sadushi‐Kolici, R., Skoro‐Sajer, N., & Lang, I. M. (2010) · European Respiratory Journal · doi:10.1183/09031936.00089610 · Cited by 117
The Pharmacological Treatment of Pulmonary Arterial Hypertension
Frumkin, L. R. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005587 · Cited by 115
Treatment of obesity: an update on anti‐obesity medications
Halpern, A., & Mancini, M. C. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00083.x · Cited by 115
Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine
Ceulemans, B., Schoonjans, A., Marchau, F., Paelinck, B. P., & Lagae, L. G. (2016) · Epilepsia · doi:10.1111/epi.13407 · Cited by 114
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
Egermayer, P., Town, G. I., & Peacock, A. (1999) · Thorax · doi:10.1136/thx.54.2.161 · Cited by 114
Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats
Ikeda, Y., Yonemitsu, Y., Kataoka, C., Kitamoto, S., Yamaoka, T., Nishida, K.-I., Takeshita, A., Egashira, K., & Sueishi, K. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00919.2001 · Cited by 114
Beneficial Effect of Diazoxide in Obese Hyperinsulinemic Adults1
Alemzadeh, R., Langley, G., Upchurch, L., Smith, P., & Slonim, A. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4852 · Cited by 112
National Trends in Antiobesity Medication Use
Stafford, R. S., & Radley, D. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1046 · Cited by 112
CLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSION
Fishman, A. P. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70278-1 · Cited by 111
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110
Echocardiographic assessment of pulmonary hypertension in Gaucher's disease
Elstein, D., Klutstein, M. W., Lahad, A., Abrahamov, A., Hadas‐Halpern, I., & Zimran, A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10194-0 · Cited by 110
Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension
Archer, S. L., Djaballah, K., Humbert, M. J. C., Weir, Ε. K., Fartoukh, M. S., DALL'AVA-SANTUCCI, J., Mercier, J., Simonneau, G., & Dinh‐Xuan, A. T. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.4.9802113 · Cited by 109
Self-citationPulmonary hypertension: therapeutic targets within the serotonin system
Dempsie, Y., & MacLean, M. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.241 · Cited by 108
α1-Adrenergic Hypothesis for Pulmonary Hypertension
Salvi, S. S. (1999) · CHEST Journal · doi:10.1378/chest.115.6.1708 · Cited by 107
Pathobiology of pulmonary arterial hypertension
Eddahibi, S., Morrell, N. W., d’Ortho, M., Naeije, R., & Adnot, S. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00081302 · Cited by 107
Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
Simonneau, G., Fartoukh, M. S., Sitbon, O., Humbert, M. J. C., Jagot, J.-L., & Hervé, P. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.195s · Cited by 107
Self-citationACCP Evidence-Based Clinical Practice Guidelines
Braman, S. S. (2016) · Cited by 105
Non‐alcoholic fatty liver disease
Alba, L. M., & Lindor, K. D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01493.x · Cited by 105
Drugs that may injure the respiratory system
Foucher, P., Biour, M., Blayac, J., Godard, P., Sgro, C., Kuhn, M. U., Vergnon, J., VERVLOET, D., Pfitzenmeyer, P., Ollagnier, M., et al. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10020265 · Cited by 105
Enhanced Pulmonary Vasodilator Reserve and Abnormal Right Ventricular
Andersen, M. J., Hwang, S., Kane, G. C., Melenovský, V., Olson, T. P., Fetterly, K. A., & Borlaug, B. A. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.002114 · Cited by 104
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Dumitrascu, R., Kulcke, C., Königshoff, M., Kouri, F. M., Yang, X., Morrell, N. W., Ghofrani, H. A., Weißmann, N., Reiter, R., Seeger, W., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00126010 · Cited by 104
Schoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B. W., Gammaitoni, A. R., Galer, B. S., Lagae, L. G., & Ceulemans, B. (2016) · European Journal of Neurology · doi:10.1111/ene.13195 · Cited by 104
Cercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., & Halpern, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.124 · Cited by 100
Recommendations on the management of pulmonary hypertension in clinical practice.
(2001) · Europe PMC (PubMed Central) · Cited by 103
Pulmonary Hypertension: Diagnosis and Management
McGoon, M. D., & Kane, G. C. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.191 · Cited by 102
New therapeutic approaches for the treatment of obesity
Saltiel, A. R. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1811 · Cited by 102
Dravet Syndrome: A Review of Current Management
Wheless, J. W., Fulton, S. P., & Mudigoudar, B. D. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.01.005 · Cited by 121
Sex and gender in pulmonary arterial hypertension
Cheron, C., McBride, S. A., Antigny, F., Girerd, B., Chouchana, M., Chaumais, M., Jaïs, X., Bertoletti, L., Sitbon, O., Weatherald, J. C., et al. (2021) · European Respiratory Review · doi:10.1183/16000617.0330-2020 · Cited by 102
Melian, E. B., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262010-00005 · Cited by 102
Food and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Rich, J. D., Thenappan, T., Freed, B. H., Patel, A. R., Thisted, R. A., Childers, R., & Archer, S. L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.071 · Cited by 100
What is pharmacoepidemiology? Definition, methods, interest and clinical applications
Montastruc, J., Bénevent, J., Montastruc, F., Bagheri, H., Despas, F., Lapeyre‐Mestre, M., & Sommet, A. (2018) · Therapies · doi:10.1016/j.therap.2018.08.001 · Cited by 99
MEDICAL THERAPY OF PULMONARY HYPERTENSION
Naeije, R., & Jean-Luc, V. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70288-4 · Cited by 99
Treatment of nonalcoholic fatty liver disease
Angulo, P. (2002) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32187-8 · Cited by 100
Coghlan, G., Corris, P. A., Gaine, S., Gatzoulis, M. Α., Gibbs, J. S. R., Haworth, S. G., Kiely, D. G., Peacock, A. J., Pepke‐Żaba, J., Elliot, C. A., et al. (2008) · Cited by 99
Drug-induced pulmonary arterial hypertension: a recent outbreak
Montani, D., Seferian, A., Savale, L., Simonneau, G., & Humbert, M. J. C. (2013) · European Respiratory Review · doi:10.1183/09059180.00003313 · Cited by 97
Self-citationBiological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
Goodman, W. K., Rudorfer, M. V., & Maser, J. D. (2017) · Routledge eBooks · doi:10.4324/9781315561073-31 · Cited by 97
Voelkel, N. F., Cool, C. D., Taraceviene-Stewart, L., Geraci, M. W., Yeager, M. E., Bull, T. M., Kasper, M. E., & Tuder, R. M. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205001-00013 · Cited by 96
Dempsie, Y., Morecroft, I., Welsh, D., MacRitchie, N. A., Herold, N., Loughlin, L., Nilsen, M., Peacock, A. J., Harmar, A. J., Bäder, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.767558 · Cited by 96
Metadata
- Authors
- Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
- Affiliations
- Jewish General Hospital (CA)
- Hôpital Antoine-Béclère (FR)
- University of Illinois Chicago (US)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Sheffield (GB)
- Hammersmith Hospital (GB)
- Maastricht University Medical Centre (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- Hôpital Pellegrin (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-08-29
- Volume
- 335
- Issue
- 9
- Pages
- 609-616
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329065056
- Cited by
- 1,162
- References
- 26
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
- FWCI
- 71.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
